Pharmacogenomic Company, OneOme, To Present at 2016 Annual Meeting of The American Society of Human Genetics (ASHG)

MINNEAPOLIS (Oct. 1, 2016) – Twin Cities-based pharmacogenomics company OneOme will present at the 2016 Annual Meeting of the American Society of Human Genetics (ASHG) in Vancouver, British Columbia.

Beginning with presentations on Oct. 19 and culminating in a workshop session on Oct. 20, OneOme’s content will focus on:

• Challenges and opportunities in implementing pharmacogenomics clinical decision support tools within diverse Electronic Medical Record (EMR) systems – Poster presentation, Wednesday, Oct. 19, 2 p.m. – 3 p.m., poster number 3193W Omics Tech section
• Validation of the OneOme RightMed pharmacogenomic test using the IntelliQube® to demonstrate an accurate method of pharmacogenomics genotyping – Poster presentation, Wednesday, Oct. 19, 3 p.m. – 4 p.m., poster number 1000W Mol. & Cyto Diagnostics section
• OneOme: Making Prescriptions Personal – Workshop presentation, Thursday, Oct. 20, 7:15 a.m. – 8:45 a.m., Room 16, East Building

“Pharmacogenomics can provide specific understanding of how individuals metabolize prescription drugs, guiding more effective prescription treatment options,” said Paul Owen, CEO of OneOme. “Our presentations at ASHG will offer an in-depth understanding of the validation process for the RightMed test and insights into how integrating support tools can provide a more dynamic use of test results.”

The RightMed test is a cost-effective, comprehensive, and clinically actionable pharmacogenomic test covering 22 genes, provided as a part of routine clinical care. The test, clinical report, and interactive online tools can help healthcare providers make timely, evidenced-based personalized prescription treatment decisions for more than 340 medications. OneOme has also developed an interpretive only report product for those clients who provide their own genotype or sequence data.

About half of the four billion prescriptions issued each year do not work as intended, and adverse drug reactions are the fourth leading cause of death in the U.S. Genetic factors have been shown to account for up to 95 percent of drug response variability.

OneOme will host a 7:15 a.m. workshop on Thursday Oct. 20 detailing the RightMed test and covering clinical applications and case studies with presentations by Dr. Don Skifter, Ph.D., OneOme, Dr. Daniel Mueller, M.D., Ph.D., Center for Addiction and Mental Health, and Jill Davies, MSc., CCGC, Director of Genetics, MedCan.

The workshop will seek to:
• Describe the RightMed pharmacogenomics test and interactive results to identify optimal drug combinations across multiple medical indications;
• Demonstrate how pharmacogenomic testing can improve patient’s immediate care in psychiatry through illustrative case examples; and
• Explore the integration of pharmacogenomics into clinical practices and strategies for creating a collaborative, interdisciplinary pharmacogenomics care team.

In addition, ASHG attendees will have the opportunity to learn how OneOme’s test results can be better incorporated into a variety of EMR systems as structured data, readily available, allowing clinical decision support tools to continually access the patient’s information at Wednesday’s 2 p.m. poster presentation. Improving utility and accessibility of pharmacogenomic results in systems such as EPIC and Cerner would provide more actionable clinical care throughout the life of the patient.

OneOme will also lead a presentation detailing the validation of the RightMed test, which included extensive testing with well-characterized research samples obtained from Coriell Institute for Medical Research and anonymous donor samples confirmed by Sanger sequencing at Eurofins Clinical Molecular Testing Services. Among the findings: full concordance with the bi-directional Sanger sequence donor samples for the 72 SNPs on the RightMed panel. Detailed results and data analysis from the validation studies will be reviewed during the Wednesday 3 p.m. poster presentation.

Available worldwide, RightMed is currently in use by Mayo Clinic Center for Individualized Medicine (CIM); in Canada through OneOme’s partnership with Medcan, Canada’s largest executive health clinic and a global leader in assessing clients’ overall well-being; and in Puerto Rico, Cuba and Dominican Republic through a partnership with High Profile Laboratory in Guaynabo, Puerto Rico. In the U.S., more than 500,000 patients at Centra Health in the Centra Medical Group Stroobants Cardiovascular Center have access to the RightMed test.

The RightMed test, which costs $249, is ordered by providers through a HIPAA-compliant portal at, where results are made available and retained. Results are tested at OneOme’s new CLIA-registered clinical laboratory in Minneapolis.

The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit